PL2218461T3 - Preparat przeciwciała przeciw cd40 i sposoby - Google Patents

Preparat przeciwciała przeciw cd40 i sposoby

Info

Publication number
PL2218461T3
PL2218461T3 PL10162787.5T PL10162787T PL2218461T3 PL 2218461 T3 PL2218461 T3 PL 2218461T3 PL 10162787 T PL10162787 T PL 10162787T PL 2218461 T3 PL2218461 T3 PL 2218461T3
Authority
PL
Poland
Prior art keywords
methods
antibody formulation
antibody
formulation
Prior art date
Application number
PL10162787.5T
Other languages
English (en)
Inventor
Vahe Bedian
John Daniel Cusmano
Ronald Paul Gladue
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34738672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2218461(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PL2218461T3 publication Critical patent/PL2218461T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
PL10162787.5T 2003-12-22 2004-12-09 Preparat przeciwciała przeciw cd40 i sposoby PL2218461T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53163903P 2003-12-22 2003-12-22

Publications (1)

Publication Number Publication Date
PL2218461T3 true PL2218461T3 (pl) 2016-09-30

Family

ID=34738672

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10162787.5T PL2218461T3 (pl) 2003-12-22 2004-12-09 Preparat przeciwciała przeciw cd40 i sposoby

Country Status (20)

Country Link
US (4) US20050136055A1 (pl)
EP (3) EP3081933A1 (pl)
JP (3) JP2007515469A (pl)
KR (2) KR20080023766A (pl)
CN (2) CN102552905A (pl)
AU (1) AU2004308749B2 (pl)
BR (1) BRPI0418029B8 (pl)
CA (2) CA2549652C (pl)
DK (1) DK2218461T3 (pl)
ES (1) ES2580002T3 (pl)
HU (1) HUE027717T2 (pl)
IL (2) IL175540A (pl)
NO (1) NO343797B1 (pl)
NZ (2) NZ583179A (pl)
PL (1) PL2218461T3 (pl)
RU (1) RU2355421C2 (pl)
SI (1) SI2218461T1 (pl)
TW (1) TWI359671B (pl)
WO (1) WO2005063289A1 (pl)
ZA (1) ZA200603804B (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AU2006329944A1 (en) * 2005-12-09 2007-07-05 Seattle Genetics, Inc. Methods of using CD40 binding agents
CN104357469B (zh) * 2006-05-03 2018-10-26 科罗拉多州立大学董事会 Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其用途
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CA2735421A1 (en) * 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
US9561214B2 (en) * 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
CN106928362B (zh) 2011-04-29 2021-10-26 埃派斯进有限公司 抗-cd40抗体及其使用方法
SG11201406592QA (en) 2012-05-04 2014-11-27 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9676861B2 (en) 2012-10-30 2017-06-13 Apexigen, Inc. Anti-CD40 antibodies and methods of use
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
EP2951209A4 (en) 2013-01-31 2016-06-22 Univ Jefferson CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF
PL3995507T3 (pl) 2013-08-08 2024-03-04 Cytune Pharma Il-15 i domena sushi il-15ralfa oparte na moldulokinach
SG10201913099YA (en) 2014-10-29 2020-02-27 Seattle Genetics Inc Dosage and administration of non-fucosylated anti-cd40 antibodies
AU2016291817A1 (en) 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
CN108778301A (zh) 2016-03-10 2018-11-09 永恒生物科技股份有限公司 通过联合疗法来治疗实体瘤或淋巴瘤的方法
FI3468997T3 (fi) 2016-06-08 2023-10-31 Xencor Inc Igg4:ään liittyvien sairauksien hoito anti-cd19-vasta-aineilla, jotka ristisitoutuvat cd32b:een
EP3471753A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 and il-2 cytokines
US11905331B2 (en) 2016-11-11 2024-02-20 Kumho Ht, Inc. Antibody binding specifically to CD40 and use thereof
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
US11242397B2 (en) 2017-06-01 2022-02-08 Pb Immune Therapeutics Inc. Anti-CD40 antibody and methods for blocking CD40-CD40L signaling
WO2018220100A1 (en) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Administration routes for immune agonists
EP3418302A1 (en) * 2017-06-19 2018-12-26 F. Hoffmann-La Roche AG Administration routes for immune agonists
AU2019255781A1 (en) * 2018-04-20 2020-10-29 Lyvgen Biopharma Holdings Limited Anti-CD40 antibodies and uses thereof
AU2019287765A1 (en) 2018-06-15 2021-01-07 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
EP3856790A4 (en) * 2018-09-28 2022-09-28 Lyvgen Biopharma Holdings Limited ANTI-CD40 BINDING MOLECULES WITH MODIFIED CF DOMAINS AND THEIR THERAPEUTIC USES
CN112839961B (zh) * 2018-11-30 2023-04-04 江苏恒瑞医药股份有限公司 一种cd40抗体药物组合物及其用途
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
JP2547556B2 (ja) * 1987-02-06 1996-10-23 株式会社 ミドリ十字 ｒ−グロブリンの液状製剤
SE8701004D0 (sv) 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
JPH03204821A (ja) * 1989-12-28 1991-09-06 Green Cross Corp:The モノクローナル抗体含有水溶液の加熱処理方法
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
WO1994004570A1 (en) 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
KR960704576A (ko) * 1993-10-01 1996-10-09 크리스토퍼 엘. 와이트 CD40에 대한 항체(Antibodies to CD40)
DE69433820T2 (de) * 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DK0999853T3 (da) * 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
DK1488806T3 (en) * 1999-06-01 2016-02-08 Biogen Ma Inc Blocking monoclonal antibody to VLA-1 and its use in the treatment of vascular disorders
WO2001047554A1 (fr) * 1999-12-28 2001-07-05 Chugai Seiyaku Kabushiki Kaisha Compositions d'anticorps stables et preparations pour injection
US6358670B1 (en) * 1999-12-28 2002-03-19 Electron Vision Corporation Enhancement of photoresist plasma etch resistance via electron beam surface cure
MXPA02007473A (es) 2000-02-01 2003-09-22 Tanox Inc Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40.
BR0109705A (pt) * 2000-03-31 2005-01-11 Idec Pharma Corp Uso combinado de anticorpos ou antagonistas anti-citocina e anticd20 para o tratamento de linfoma de célula b
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) * 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
AU2002211366A1 (en) * 2000-10-02 2002-04-15 Chiron Corporation Human anti-cd40 antibodies
PT1324776E (pt) * 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
EP1409018B1 (en) * 2001-07-25 2010-01-06 Facet Biotech Corporation Stable lyophilized pharmaceutical formulation the igg antibody daclizumab
US20030138417A1 (en) * 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
ES2307832T3 (es) * 2001-12-03 2008-12-01 Amgen Fremont Inc. Clasificacion de anticuerpos basada en las caracteristicas de union.
US7115108B2 (en) 2002-04-02 2006-10-03 Becton, Dickinson And Company Method and device for intradermally delivering a substance
US20080009439A1 (en) * 2002-11-05 2008-01-10 Alsobrook John P Compositions and Methods of Use for a Fibroblast Growth Factor
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET

Also Published As

Publication number Publication date
US20050136055A1 (en) 2005-06-23
CN1897971A (zh) 2007-01-17
AU2004308749B2 (en) 2010-10-28
US20110104182A1 (en) 2011-05-05
NO343797B1 (no) 2019-06-11
EP2218461B1 (en) 2016-04-20
IL201409A0 (en) 2010-05-31
JP2007515469A (ja) 2007-06-14
WO2005063289A1 (en) 2005-07-14
NZ583179A (en) 2011-06-30
JP2011184446A (ja) 2011-09-22
HUE027717T2 (en) 2016-10-28
EP1706143A1 (en) 2006-10-04
SI2218461T1 (sl) 2016-08-31
JP2014205692A (ja) 2014-10-30
KR20080023766A (ko) 2008-03-14
KR100847944B1 (ko) 2008-07-22
JP5634321B2 (ja) 2014-12-03
US20120263732A1 (en) 2012-10-18
RU2006120950A (ru) 2008-01-27
KR20070012626A (ko) 2007-01-26
TW200521142A (en) 2005-07-01
BRPI0418029B8 (pt) 2021-05-25
NZ547162A (en) 2010-03-26
IL175540A0 (en) 2006-09-05
DK2218461T3 (en) 2016-05-17
CA2549652A1 (en) 2005-07-14
CA2704300A1 (en) 2005-07-14
NO20063373L (no) 2006-09-21
RU2355421C2 (ru) 2009-05-20
CA2549652C (en) 2013-11-12
US20090311254A1 (en) 2009-12-17
EP3081933A1 (en) 2016-10-19
AU2004308749A1 (en) 2005-07-14
TWI359671B (en) 2012-03-11
EP2218461A1 (en) 2010-08-18
ZA200603804B (en) 2007-09-26
CN102552905A (zh) 2012-07-11
ES2580002T3 (es) 2016-08-18
BRPI0418029B1 (pt) 2018-12-26
BRPI0418029A (pt) 2007-04-17
IL175540A (en) 2011-10-31

Similar Documents

Publication Publication Date Title
IL175540A0 (en) Cd40 antibody formulation and methods
EP1638977A4 (en) SALINOSPORAMIDES AND METHODS OF USE
ZA200603882B (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
IL175491A0 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
GB0411940D0 (en) Methods and compositions
IL173585A0 (en) Sample preparation methods and devices
EP1701725A4 (en) PROCESS AND COMPOSITIONS
AU2003303837A1 (en) Handwriting-input device and method
EP1643907A4 (en) DEVICES AND METHOD FOR MEASURING LIGHT
HK1088837A1 (en) Clk-peptide and slk-peptide
EP1699485A4 (en) ANTI-HYDROLYSATE ANTIBODIES AND ITS USES
IL172704A0 (en) Salinosporamides and methods for use thereof
EP1679739A4 (en) DEVICE AND METHOD FOR DECOLATING SHEET
IL172510A0 (en) Antibodies and uses thereof
GB0318448D0 (en) Formulation
EP1589033A4 (en) ANTIBODY AND ITS USE
GB0312195D0 (en) Formulation
GB0320522D0 (en) Formulation
GB0318546D0 (en) Quinoxalinones and their use
GB0303876D0 (en) Formulation
GB0300764D0 (en) Device and method
GB0312747D0 (en) Products and methods
EP1627888A4 (en) ANTIBODY AND ITS USE
GB0306127D0 (en) Method and device
HK1169120A1 (zh) 孢菌酰胺及其使用方法